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SUMMARY
Lung and liver cancers are among the most deadly types of cancer. Despite improvements in treatment over
the past few decades, patient survival remains poor, underlining the need for development of targeted ther-
apies. MicroRNAs represent a class of small RNAs frequently deregulated in human malignancies. We now
report that miR-221&222 are overexpressed in aggressive non-small cell lung cancer and hepatocarcinoma
cells, as compared with less invasive and/or normal lung and liver cells. We show thatmiR-221&222, by tar-
geting PTEN and TIMP3 tumor suppressors, induce TRAIL resistance and enhance cellular migration through
the activation of the AKT pathway and metallopeptidases. Finally, we demonstrate that theMET oncogene is
involved in miR-221&222 activation through the c-Jun transcription factor.INTRODUCTION
Despite advances in early detection and standard treatment,
non-small cell lung cancer (NSCLC) and hepatocellular carci-
noma (HCC) are often diagnosed at an advanced stage and
have poor prognoses. The development of innovative, targeted
therapies may represent an alternative for the treatment of these
cancers. Promoting apoptosis is a possible goal for drug devel-
opment (Fesik, 2005). TNF-related apoptosis-inducing ligand
(TRAIL) is currently being tested in clinical trials; however, the
resistance of many tumors, including NSCLC and HCC, to TRAIL
represents obstacles to its clinical application. Recently, the
discovery of microRNAs (miRNAs) has expanded our knowledge
regarding the complex control of gene expression; miRNAs are
small non-coding RNAs of 19–25 nt that can block mRNA trans-498 Cancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inclation and/or negatively regulate its stability (Ambros, 2004). At
this time, over 500 different miRNAs have been identified in
human cells (Griffiths-Jones et al., 2006) and evidence indicates
that regulation of miRNA levels is very important for proper
growth and differentiation of many cell types and tissues (Bartel,
2004; Krichevsky et al., 2003). Dysregulated miRNA expression
is a common feature of solid and hematopoietic malignancies
(Calin et al., 2002; Ruvkun, 2006), and there is strong evidence
that they function as a class of oncogenes or tumor suppressor
genes (Calin and Croce, 2006). PTEN is one of the most
commonly altered tumor suppressors in human cancers and
a key regulator of cell growth and apoptosis (Di Cristofano and
Pandolfi, 2000). Functionally, PTEN converts phosphatidylinosi-
tol-3,4,5-trisphosphate in the cytoplasm to phosphatidylinositol-
4,5-bisphosphate, thereby directly antagonizing the activity ofSIGNIFICANCE
Drug resistance and tumor metastasis represent the main obstacles to successful cancer treatment. MicroRNAs are small
noncoding RNAs that show expression loss or gain inmost cancers, and there is growing evidence that they play substantial
roles in the pathogenesis and prognosis of human malignancies. In this study we found that MET, through Jun transcrip-
tional activation, upregulates miR-221&222 expression, which, in turn, by targeting PTEN and TIMP3, confers resistance
to TRAIL-induced cell death and enhances tumorigenicity of lung and liver cancer cells. The results suggest that therapeutic
intervention, involving the use of microRNAs, should not only sensitize tumor cells to drug-inducing apoptosis but also
inhibit their survival, proliferation, and invasive capabilities..
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MET Induces Tumorigenesis Through miR-221&222phosphatidylinositol 3-OH kinase (PI3K) (Leevers, 1999). Its inac-
tivation results in constitutive activation of the PI3K/AKT
pathway and in subsequent increase in protein synthesis, cell-
cycle progression, migration, and survival (Li and Sun, 1998).
In addition, various studies have demonstrated that the protein
phosphatase activity of PTEN inhibits activation of mitogen-acti-
vated protein kinase via several pathways (Lee et al., 2005; Saito
et al., 2003). The matrix metalloproteinases (MMPs) are a family
of zinc proteases involved in the breakdown of extracellular
matrix in normal physiological processes, such as embryonic
development, tissue and bone remodeling, wound healing, and
angiogenesis. (Nagase et al., 2006; Chakraborti et al., 2003).
Within the extracellular matrix, the tissue inhibitors of metallopro-
teinases (TIMPs), of which there are four family members
(TIMP1–4) (Cruz-Munoz and Khokha, 2008), inhibit the activity
of MMPs by binding with a 1:1 stoichiometry to the active site
(Bode et al., 1994). Previous studies have shown that overex-
pression of TIMP3 in vascular smooth muscle cells and mela-
noma cell lines inhibits invasion and promotes apoptotic cell
death (Ahonen et al., 1998; Baker et al., 1998). MET, also known
as c-Met, is a membrane receptor for the hepatocyte growth
factor (HGF)/scatter factor. MET is normally expressed by cells
of epithelial origin, while expression of HGF is restricted to cells
of mesenchymal origin. Upon HGF stimulation, MET stimulates
the invasive growth of cancer cells and increases their meta-
static potential, principally through increased phosphorylation
of ERK1/2 and JNK (Song et al., 2007). Phosphorylated JNKs
activate the oncoprotein c-Jun, which is known to form the
activator protein-1 (AP-1) transcription factor as a homodimer
or heterodimer with its partner c-Fos. Aberrant expression of
HGF/scatter factor and its receptor MET often correlates with
poor prognosis in a variety of human malignancies. In this study,
we investigated, by in vitro and in vivo experiments, the role of
miR-221&222 in TRAIL resistance and tumorigenesis of NSCLC
and HCC and their regulation through c-Met oncogene.
RESULTS
MiR-221 andmiR-222 Directly Target PTEN
and TIMP3 30UTRs
In a previous study, to identify mechanisms implicated in TRAIL
resistance, we determined the miRNA expression profile in four
NSCLC cell lines. We found thatmiR-221 andmiR-222 are mark-
edly upregulated in TRAIL-resistant (Calu-1) and semi-resistant
(A459 and A549), versus TRAIL-sensitive, NSCLC cells (H460).
The results indicated that miR-221&222 modulate TRAIL sensi-
tivity in lung cancer cells mainly by interfering with p27kip1
expression and TRAIL-induced caspase machinery (Garofalo
et al., 2008a). To identify miR-221 and miR-222 targets, we
performed a bioinformatics search (Targetscan, Pictar, RNhy-
brid) for putative mRNA targets of both miRNAs. Among the
candidate targets, 30UTRs of human PTEN (nucleotides 200–
207; NM_000314) and human TIMP3 (nucleotides 2443–2449;
NM_000362) contained regions that matched the seed se-
quences of hsa-miR-221 and miR-222 (Figure 1A). To verify
that PTEN and TIMP3 are direct targets of miR-221&222,
PTEN and TIMP3 30UTR, containing the miR-221&222 binding
sites, were cloned downstream of the luciferase open reading
frame. These reporter constructs were used to transfectCMEG01 cells, which express very low levels of miR-221&222
(Figure 1B) and are highly transfectable (Freson et al., 2005).
Increased expression of these miRs upon transfection, con-
firmed by qRT-PCR (Figure 1B), significantly affected luciferase
expression, measured as relative luciferase activity (Figure 1C).
Conversely, when we performed luciferase assays using
a plasmid harboring the 30UTR of PTEN and TIMP3 mRNAs,
where the binding sites for miR-221 and miR-222 were inacti-
vated by site-directed mutagenesis, we observed a consistent
reduction in miR-221&222 inhibitory effect (Figure 1C). To deter-
mine if these miRNAs affect PTEN and TIMP3 expression in the
H460 cellular environment, we analyzed the consequences of
the ectopic expression of miR-221&222 in H460 cells. Increased
expression of these miRs upon transfection was confirmed by
qRT-PCR (Figure 1D), and then the effects on endogenous levels
of PTEN and TIMP3 were analyzed by western blot (Figure 1E).
MiR-221&222 overexpression significantly reduced the endoge-
nous levels of PTEN and TIMP3 compared to H460 cells trans-
fected with scrambled pre-miR. Conversely, knockdown of miR-
221&222 by 20-O-me-anti-miR-221 and 20-O-me-anti- miR-222,
confirmed by quantitative RT-PCR (qRT-PCR) (Figure 1F) in
Calu-1 lung-derived cells with high levels of endogenous miR-
221&222, increased the protein levels of PTEN and TIMP3
(Figure 1G). Intriguingly, by qRT-PCR, we found that PTEN,
but not TIMP3, mRNA levels were strongly reduced in the
miR-221&222 transfected cells (Figure 1H), indicating that
miR-221&222 induce the degradation of PTEN mRNA while
TIMP3 is regulated by these miRNAs only at the translational
level. In summary, these results supported the bioinformatics
predictions indicating PTEN and TIMP3 30UTRs as direct targets
of miR-221 and miR-222.
MiR-221 andmiR-222 Are Inversely Correlated
with PTEN and TIMP3 Expression in NSCLC and HCC
Since PTEN is a major tumor suppressor, and since miR-
221&222 are upregulated in human hepatocarcinoma cells
(Fornari et al., 2008), we decided to evaluate the endogenous
levels of miR-221 and miR-222 by northern blot in large panels
of primary NSCLCs and HCCs, compared with the normal coun-
terpart. MiR-221&222 expression was almost undetectable in
normal lung and liver cells but highly expressed in the majority
of tumor cell lines. Moreover, we found, as assessed by western
blot, an inverse correlation between miR-221&222 RNA expres-
sion and PTEN and TIMP3 protein expression in most cell lines
analyzed (Figure 2A), confirmed also by qRT-PCR (Figure 2B).
We did not check by qRT-PCR TIMP3 mRNA expression levels
because we did not observe downregulation of TIMP3 mRNA
after enforced miR-221&222 expression (Figure 1H). These
results suggested that high expression of miR-221 and miR-
222 might be one of the mechanisms acting to negatively regu-
late PTEN and TIMP3 in NSCLC and HCC. To verify whether
these miRNAs affected PTEN and TIMP3 endogenous levels
also in HCC, we analyzed the effects of the ectopic expression
of miR-221 and miR-222 in the Sk-Hep1 cell line, which
expresses low levels of miR-221&222. As shown in Figure 3A,
PTEN and TIMP3 proteins were clearly reduced in Sk-Hep1 cells
uponmiR-221 andmiR-222 overexpression. Conversely, knock-
down of miR-221&222 by 20-O-me-anti-miR-221 and 20-O-me-
anti-miR-222 in Snu-387 cells, which expressed high levels ofancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc. 499
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MET Induces Tumorigenesis Through miR-221&222Figure 1. PTEN and TIMP3 Are Targets of miR-221&222
(A) PTEN and TIMP3 30UTRs contain one predicted miR-221 and miR-222 binding site. In the figure the alignment of the seed regions of miR-221&222 with PTEN
and TIMP3 30UTRs is shown. The sites of target mutagenesis are indicated in red.
(B) qRT-PCR in MEG01 cells after enforced expression of miR-221 and miR-222.
(C) PTEN and TIMP3 30UTRs are targets of miR-221&222. pGL3-PTEN and pGL3-TIMP3 luciferase constructs, containing a wild-type (left side of the histograms)
or mutated (right side of the histograms) PTEN and TIMP3 30UTRs, were transfected into MEG01 cells. Relative repression of firefly luciferase expression was
standardized to a transfection control. The reporter assays were performed three times with essentially identical results.
(D) qRT-PCR in H460 cells after enforced expression of miR-221 and miR-222.
(E) miR-221&222-enforced expression decreases endogenous levels of PTEN and TIMP3 proteins in H460 NSCLC. H460 cells were transfected with either
scrambled,miR-221, ormiR-222 for 72 hr. PTEN and TIMP3 expression was assessed by western blot. Loading control was obtained using anti-b-actin antibody.
(F) qRT-PCR showing miR-221&222 downmodulation in Calu-1 cells after anti-miRs transfection.
(G) Western blot showing PTEN and TIMP3 expression aftermiR-221&222 downregulation using anti-miR-221&222. Anti-miR-221 and anti-miR-222were able to
increase PTEN and TIMP3 expression in Calu-1 cell line.
(H) qRT-PCR ofPTEN and TIMP3mRNA aftermiR-221 andmiR-222 forced expression in H460 cells. PTEN but not TIMP3mRNA was downregulated bymiR-221
and miR-222. Data are presented as ± SD.endogenous miR-221&222, increased the protein level of PTEN
and TIMP3 (Figure 3A). Having noted thatmiR-221&222 downre-
gulate PTEN and TIMP3 expression in both NSCLC and HCC-
derived cells in culture, we wondered if this regulation also
occurs in vivo. To answer this question, we investigated PTEN
mRNA and miR-221&222 expression by qRT-PCR in primary
lung tumor specimens, in comparison with normal human lung
tissue samples. MiR-221 and miR-222 were almost undetect-
able in normal human lung samples and highly expressed in all
the tumor samples analyzed. Of the 22 primary lung tumors
examined, in fact, all of them exhibited downregulation of
PTEN and overexpression of miR-221&222 (Figure 3B). These
data further support the finding that PTEN is a direct target
of miR-221&222 also in vivo. To corroborate these findings,
in situ hybridization analysis was performed using 50-dig-labeled
LNA probes on hepatocarcinoma and normal liver tissues,
followed by immunohistochemistry for PTEN and TIMP3
(Figure 3C). MiR-221&222 and PTEN/TIMP3 expressions were
inversely related in liver cancers and the adjacent normal/
cirrhotic liver tissues. Liver cancer cells showed high expression500 Cancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc.of miR-221&222 and rarely expressed PTEN or TIMP3 (Fig-
ure 3Cg, 3Ch, 3Ck, and 3Cl), whereas the adjacent non-malig-
nant liver expressed PTEN and TIMP3 abundantly and rarely
showed detectable miR-221&222 signal (Figure 3C, a, b, e,
and f). MiR-221&222 and PTEN/TIMP3 expression were also
inversely related in lung cancers and the adjacent normal lung
tissues (see Figure S1 available online). The majority of cancer
cells were positive for miR-221 and miR-222 and negative for
PTEN (Figure S1F and S1G) and TIMP3 (Figure S1I and S1J). In
Figure S1I and S1J, miRNA expression was evident in the cancer
cells and TIMP3 expression in the surrounding cells. A strong
miR-222 signal (Figure S1, large arrow) was found in the nests
of tumor cells that are infiltrating the adjacent fibrotic lung tissue
(Figure S1K and S1L).
MiR-221&222 Induce TRAIL Resistance in NSCLC
and HCC by Targeting PTEN and TIMP3
Since PTEN regulates the PI3K/AKT pathway, which plays a key
role in multiple drug resistance (Garofalo et al., 2008b), including
TRAIL (Kandasamy and Srivastava, 2002), and since TIMP3 is
Cancer Cell
MET Induces Tumorigenesis Through miR-221&222involved in apoptosis through activation of caspases (Lee et al.,
2008a), we next examined the effects of miR-221&222 and/or
PTEN-TIMP3 silencing on cell survival and TRAIL resistance in
both NSCLC and HCC. First we performed a proliferation assay
on five HCC-derived cell lines, three of them (HepG2, Sk-Hep1,
and Huh 7) with low miR-221&222 expression and two (PLC/
PRF-5 and Snu-387) with high miR-221&222 expression level
(Figure 4A). Cells were exposed to TRAIL for 24 hr and then
cell proliferation was assessed using an MTT assay. Interest-
ingly, cells expressing low levels of miR-221&222 underwent
TRAIL-induced cell death, showing a very low proliferation
rate, whereas cells overexpressing miR-221&222 did not display
sensitivity when exposed to soluble TRAIL (Figure 4A). More-
over, Annexin-FITC and caspase 3/7 assays on TRAIL-sensitive
cell lines Sk-Hep1 cells, (Figures 4B and 4C), HepG2, and Huh7
(Figures S2A and S2B) revealed an increase of about 30%–40%
in TRAIL resistance after miR-221&222 overexpression, as well
as after PTEN and TIMP3 silencing by PTEN and TIMP3 siRNAs.
TRAIL-sensitive H460 cells also became more resistant to
TRAIL-inducing apoptosis after PTEN and TIMP3 knockdown,
as determined by caspase 3/7 activity (Figure 4D) and An-
nexin-FITC assay (Figure 4E), although PTEN silencing was
more effective than TIMP3. Moreover, to further evaluate the
contribution of these targets on TRAIL-inducing apoptosis,
PTEN and TIMP3 sequences were cloned in pCruz-HA plasmid
(Santa Cruz Biotechnology, Inc.) and used to transfect Calu-1
TRAIL-resistant cells. Calu-1 cells became more sensitive to
TRAIL-inducing apoptosis after PTEN and TIMP3 restoration,
alone or in combination, as determined by caspase 3/7 activity
(Figure 4D) and Annexin-FITC staining (Figures S3A and S3B).
To further investigate the role of TIMP3 in TRAIL-inducing
apoptosis the expression of caspase-3, -8, and -9, poly-ADP-
ribose polymerase, and some of the molecules involved in the
TRAIL-signaling pathway were tested by western blot after
TIMP3 overexpression in the Calu-1 cell line (Figure S3C). Inter-
estingly, the activation of poly-ADP-ribose polymerase and the
Figure 2. PTEN and TIMP3 Expression Is
Inversely Related to that of miR-221&222 in
NSCLC and HCC
(A) miR-221 and miR-222 expression levels were
assessed by northern blot analysis using 15 mg
of total RNA for NSCLC and 10 mg of total RNA
for HCC cells. Western blots of anti-PTEN and
TIMP3 were performed using total protein extract
(50 mg) isolated from the different NSCLCs and
HCCs.
(B) qRT-PCR of miR-221&222 and PTEN mRNA
was performed by extracting RNA from the
different NSCLC and HCC cells as described in
the Supplemental Experimental Procedures.
miR-221&222 were inversely related to PTEN
mRNA expression in all the different NSCLC and
HCC cells. Data are presented as ± SD.
caspase cascade were observed, as as-
sessed by the appearance of the cleaved
fragments. Moreover, Mcl-1 expression
was downregulated while cytochrome c
expression increased (Figure S3C). All
together these results suggest an involvement of TIMP3 in
both the extrinsic and intrinsic apoptotic pathways and highlight
its role in TRAIL-inducing apoptosis. The same results were ob-
tained after TIMP3 restoration in Snu-387 cells (data not shown).
Because AKT is regulated by PI3K signaling and has been shown
to be hyperactivated through the loss of PTEN, we investigated
by immunostaining the expression and/or the activation of
some of the proteins involved in the PI3K/AKT pathway after
miR-221&222 enforced expression in H460 cells or after miR-
221&222 silencing in Snu-387 cells. As shown in Figure 5A, the
expression levels of PI3K, AKT, and its phosphorylated sub-
strate, phospho-glycogen synthase kinase 3b, were elevated
by ectopic expression of miR-221&222 and, in contrast, were
decreased by knockdown of miR-221&222 in Snu-387 cells,
suggesting that miR-221&222 target the PTEN/AKT pathway
(Figure 5B). Since miR-221&222 has been suggested to induce
tumorigenesis (Felicetti et al., 2008) and PTEN downregulation
of phosphorylation influences the activation of proteins, such
as ERKs and PAK1, involved in cellular migration and invasion
(Lee et al., 2008b; Chan et al., 2008), we investigated the
activation and expression levels of these proteins. We found
an increase in ERK phosphorylation and PAK1 expression, as
compared with H460 cells transfected with the control miR (Fig-
ure 5C). Interestingly, increased expression of metallopeptidase
3 and metallopeptidase 9 was also found, possibly a result of
TIMP3 downregulation (Figures 5A–5C). To test if the activation
of the previous proteins was PTEN and/or TIMP3 dependent,
we silenced PTEN and TIMP3 in H460 cells. As shown in Figures
5D and 5E, the activation of the ERKs and PAK1 is both PTEN
and TIMP3 dependent, while AKT phosphorylation is PTEN
dependent and MMP3 and MMP9 are upregulated after TIMP3
knockdown. Finally, because ectopic expression of miR-
221&222 reduces PTEN levels, leading to activation of the AKT
pathway and inhibition of TRAIL-induced cell death, we
wondered if AKT inhibition could overridemiR-221&222-induced
cell survival and TRAIL resistance. Calu-1 and Snu-387 wereCancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc. 501
Cancer Cell
MET Induces Tumorigenesis Through miR-221&222Figure 3. PTEN and TIMP3 Are Direct Targets of miR-221&222 in HCC In Vitro and In Vivo
(A) Western blot showing PTEN and TIMP3 expression in Sk-Hep1 and Snu-387 cells after miR-221&222 overexpression or downregulation. MiR-221 and
miR-222 were able to downregulate PTEN and TIMP3 expression in Sk-Hep1; conversely, anti-miR-221&222 were able to increase PTEN and TIMP3 expression
in Snu-387 cells.
(B) qRT-PCR on 22 lung cancer patients and 10 normal lung tissues. The association between miR-221&222 and PTEN mRNA for the 10 subjects in the normal
class and for the 22 subjects in the tumor class was calculated statistically using the Pearson correlation coefficient (r) and the respective p value, all significant at
p < 0.05. The Pearson correlation indicated an inverse relation between miR-221, miR-222, and PTEN mRNA in the normal and tumor samples.
(C) Immunohistochemistry and in situ hybridization on hepatocarcinoma and normal liver tissues samples. miR-221&222 (blue) and PTEN/TIMP3 (red) expression
were inversely related in liver cancers and the adjacent normal/cirrhotic liver tissues. These tissues were analyzed for miR-221 and miR-222 expression by in situ
hybridization, followed by immunohistochemistry for PTEN and TIMP3. Liver cancer cells abundantly expressed miR-221&222 and rarely expressed PTEN or
TIMP3 (Cg, Ch, Ck, and Cl), whereas the adjacent non-malignant liver abundantly expressed PTEN or TIMP3 and rarely had detectable miR-221&222 (Ca,
Cb, Ce, and Cf). In the cases of HCC, where both miR-221&222 and TIMP3 expression were noted, the cancer cells expressing miR-221 (Ck, large arrow;
TIMP3 is depicted by arrow in l) were distinct from those cells expressing TIMP3 (Ck, small arrow). (Cc–Ci) H&E. (Cd–Cj) MiR-302, which is not express in liver,
was used as negative control. 80 human HCCs were analyzed. Scale bars indicate 25 mm.transfected with 20-O-methyl (20-O-me)-anti-miR-221&222oligor-
ibonucleotides. Cells transfected with 20-O-me-scrambled miR
were used as control. BlockingmiR-221&222 expression consid-
erably sensitized these cells to TRAIL-induced apoptosis, as as-
sessed by caspase 3/7 assay (Figures 5F and 5G). Moreover,
Calu-1 and Snu-387 cells were treated with the specific AKT inhib-
itor, API-2/triciribine (Yang et al., 2004), with or without TRAIL. As
shown in Figures 5F and 5G, API-2 abrogatedmiR-221&222-acti-
vated AKT and significantly inhibited miR-221&222-induced cell
survival and TRAIL resistance. Next, to directly compare the
growth of tumors with and without PTEN and TIMP3, we used
short hairpin RNA (shRNA) constructs designed to knockdown
gene expression to silence PTEN and TIMP3 in H460 cells. An
shRNA plasmid, encoding a scrambled shRNA sequence that
does not lead to the specific degradation of any known cellular
mRNA, was used as control. We assessed the consequences of502 Cancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier IncPTEN and TIMP3 disruption on tumor growth and TRAIL resis-
tance in vivo by implanting H460 PTEN and TIMP3 knockdown
cells into the right dorsal sides of nude mice. TRAIL treatment
was initiated 5 days afterwards, when lung carcinoma had been
established. PTEN and TIMP3 loss (Figure S4A) conferred not
only a significant tumor growth advantage but also resistance to
TRAIL-inducing apoptosis over control tumors (Figures S4B–
S4G). These findings led us to conclude that PTEN and TIMP3
are important targets in TRAIL resistance and could play an
important role in tumorigenicity of NSCLC and HCC cells.
PTEN and TIMP3 Downregulation bymiR-221&222
Induces Migration and Invasiveness
in NSCLC and HCC Cells
To directly test the functional role of miR-221&222 in tumorigen-
esis, we overexpressed these two miRNAs or silencedPTEN and.
Cancer Cell
MET Induces Tumorigenesis Through miR-221&222Figure 4. MiR-221&222 Induce TRAIL Resis-
tance in NSCLC and HCC by Targeting
PTEN and TIMP3
(A) Proliferation assay on five different HCCs. Cells
were incubated with Super-Killer TRAIL (400 ng/ml)
for 24 hr and viability was evaluated as described in
the Supplemental Experimental Procedures.
Huh7, HepG2, and Sk-Hep1 with low miR-221
and miR-222 expression were more sensitive
to TRAIL-induced apoptosis compared to PLC/
PLF-5 and Snu-387, highly expressing miR-
221&222. Mean ± SD of four independent experi-
ments repeated in triplicate.
(B) Cell death effects in Sk-Hep1 cells after miR-
221&222 forced expression and PTEN or TIMP3
downregulation. Cells were transfected either with
control miR or withpre-miR-221&222. Twenty-four
hours after transfection, cells were treated with
Super-Killer TRAIL for 24 hr. Apoptosis was evalu-
ated either with Annexin-FITC or with caspase-Glo
3/7 kit.
(C) TRAIL resistance increased after miR-221&222
overexpression or PTEN and TIMP3 downmodu-
lation.
(D) Effects of miR-221&222 on cell death. H460
cells were transfected either with control siRNA
or control miR or with 100 nmol of PTEN and
TIMP3 siRNA. After 48 hr from the transfection,
cells were treated with Super-Killer TRAIL for 24 hr.
(E) Apoptosis was evaluated by caspase 3/7
activity or Annexin-V.
The percentage of apoptotic cells decreased after
PTEN and TIMP3 downregulation. Error bars indi-
cate ± SD. *p < 0.05 and **p < 0.001 by Student’s
t test.TIMP3 in H460 and Sk-Hep1 cells. Then, by cell-cycle analysis,
miR-221&222 and PTEN siRNA H460 transfected cells showed
a decrease of G1 and a corresponding increase of the S and
G2-M phases (Figure 6A). After 72 hr of transfection, the analysis
revealed an earlier onset of DNA synthesis induced by miR-221
and miR-222 or PTEN knockdown, paralleled by a faster reduc-
tion of G1 cells, contributing to the proliferative advantage (Fig-
ure 6A). The same change was observed in Sk-Hep1 cells (Fig-
ure S5A). Next, we analyzed the effects of miR-221 and
miR-222 overexpression on cellular migration and invasion of
NSCLC and HCC cells. Interestingly, we observed a significant
increase on the migratory (Figures 6B and 6C) and invasive
(Figure 6D) capabilities of H460 and Sk-Hep1 (Figure S5B) cells
after miR-221&222 overexpression as well after PTEN and
TIMP3 downregulation. Conversely, when we downregulated
miR-221&222 by transfection with 20-O-me-anti-miR-221&222,
we observed a decrease in cell migration and invasion in both
Calu-1 and Snu-387 cells (Figures S6A and S6B).
MET Controls miR-221&222 Activation through
AP-1 Transcription Factor
Activation of MET signaling is a frequent event observed in many
types of cancers, including lung and liver. MET receptor
promotes a complex biological program designated ‘‘invasive
growth’’ that results from stimulation of cell motility, invasion,
and protection from apoptosis. Several studies have shown
that MET induces tumor cell migration/invasion through the acti-Cvation of the PI3K/AKT pathway (Segarra et al., 2006; Zhou et al.,
2008), so we determined if MET could induce PTEN downregu-
lation and AKT activation through miR-221&222. To test this
hypothesis, we silenced MET, by using siRNA, in Calu-1 and
Snu-387 cells and in a gastric cell line (GTL16) previously
reported to overexpress MET oncogene because of DNA ampli-
fication (Giordano et al., 1989). First, miR-221&222 expression
levels were evaluated by qRT-PCR. After MET knockdown,
miR-221&222 expression was downregulated in all cell lines
analyzed (Figures 7A–7C). The same result was obtained by
treating GTL16 cells with a MET inhibitor, SU11274 (Figure S7A).
Second, by immunostaining, we observed increased PTEN and
TIMP3 expression levels after MET downregulation or inhibition,
a further hint that MET is involved in miR-221&222 activation
(Figures 7D–7F). Next, we were interested in determining how
MET could be involved in miR-221&222 regulation. By bioinfor-
matics search (TESS database: http://www.cbil.upenn.edu/
cgi-bin/tess/tess), we found that the only transcription factor
involved in the MET pathway predicted to bind and transcription-
ally activate miR-221&222 promoter was AP-1. AP-1 is a dimeric
basic region leucine zipper protein that belongs to the Jun and
Fos subfamilies. c-Jun is the most potent transcriptional acti-
vator in its group (Ryseck and Bravo, 1991). To define which
factor, belonging to the AP-1 family, was involved in miR-
221&222 transcriptional activation, we began with analysis of
c-Jun and c-Fos. First, we investigated the correlation between
miR-221&222 expression and c-Jun and c-Fos protein levels inancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc. 503
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MET Induces Tumorigenesis Through miR-221&222Figure 5. Anti-miR-221&222 Override TRAIL Resistance in NSCLC and HCC through the Inhibition of the AKT Pathway
(A–C) Western blots in H460 cells after miR-221&222 forced expression. MiR-221&222 forced expression induces the activation of the AKT/ERKs pathways and
metallopeptidases. (B) Western blots in Snu-387 cells aftermiR-221&222 knockdown by anti-miR-221&222. The inhibition of the AKT pathway is shown as a result
of miR-221&222 downregulation.
(D and E) Western blots after PTEN or TIMP3 knockdown. Erks phosphorylation and PAK1 activation are both PTEN and TIMP3 dependent. The activation of the
AKT pathway is PTEN dependent, while TIMP3 silencing induces the expression of metallopeptidases.
(F and G) Effects of anti-miRs and AKT pathway inhibition by API2/triciribine on cell death. Calu-1 and Snu-387 cells were transfected with anti-miR-221&222 for
72 hr or treated with API2/triciribine for 48 hr. MiR-221&222 downmodulation and/or the inhibition of the Akt pathway induced an increase in apoptosis
percentage in both Calu-1 and Snu-387 cell lines, as assessed by caspase 3/7 activity. Error bars indicate ± SD. **p < 0.001 by Student’s t test.four different cell lines (H460, Calu-1, Huh7, and Snu-387)
(Figure S7B). Calu-1 cells, highly expressing c-Jun and c-Fos,
were cotransfected with MET siRNA, c-Jun siRNA, or c-Fos
siRNA. Subsequent qRT-PCR amplification showed that MET
and c-Jun downregulation, but not c-Fos knockdown, gave
rise to a reduction of 45%–50% in miR-221&222 expression
levels, as compared with the negative control (Figure S7C). To
further confirm these results we carried out luciferase assays.
In previous work, we found that miR-221&222 are transcribed
into a single species of 2.1 kb RNA and the transcription is regu-
lated by the upstream sequence located at 150 bp/50 bp
from the 50 end of miR-222 hairpin structure (Di Leva et al.,
2009). To determine if the previously identified miR-221&222
promoter region was affected by MET/AP-1, we performed
luciferase assay using the reporter plasmids containing the frag-
ments spanning +3 to 150, +3 to 600, and +3 to 1000
(+1 position corresponds to the 50 terminus of miR-222 hairpin)
(Figure 7G) into the pGL3basic vector, which harbors the promo-
terless luciferase gene (Di Leva et al., 2009). The pGL3b, 150,
600, and 1000 pGL3b were cotransfected with MET siRNA,
c-Jun siRNA, or c-Fos siRNA into Calu-1 cells (Figures S7D
and S7E). Subsequent luciferase assays showed that MET and
c-Jun downregulation gave rise to a reduction of 45% in lucif-504 Cancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc.erase activity, as compared to the basal activity determined by
transfection with pGL3b empty vector; we did not observe
a reduction of luciferase activity after c-Fos siRNA transfection
(Figures S7D and S7E). Together these data led us to conclude
that c-Jun and not c-Fos is the transcription factor involved in
the MET pathway responsible for miR-221&222 activation in
NSCLC and HCC cells. Since we noticed that the promoter
region was responsive to c-Jun modulation, to verify a direct
binding of c-Jun onmiR-221&222 promoter, we carried out chro-
matin immunoprecipitation (ChIP) assays. First, by bioinfor-
matics analysis, we found only one AP-1 putative binding site
located 130 bp upstream of the pre-miR-222 50 end. Taking
into account the predicted AP-1 binding site, a total of two chro-
matin regions were analyzed (Figure 7G): one spanning the AP-1
binding site and the second, as negative control, 1700 nt
upstream of the pre-miR-222 50 end, where we did not find any
predicted binding site for AP-1. As expected, ChIP assay of
c-Jun-positive Calu-1 and Snu-387 cells showed remarkable
AP-1 binding at ChIP analyzed region 2, proximal to the promoter
(Figures 7H and 7I). No chromatin enrichment by c-Jun ChIP was
observed in c-Jun-negative H460 cells, verifying the specificity
of the ChIP assay. Finally, because the induction of AP-1 is
mostly mediated by the JNK-MAP kinase cascades we treated
Cancer Cell
MET Induces Tumorigenesis Through miR-221&222Figure 6. Ectopic Expression ofmiR-221 andmiR-222 Affects the Cell-Cycle Distribution and Migration/Invasion Capabilities of H460 Cells
(A) Flow cytometric distributions of H460 cells transfected with pre-miR scrambled, miR-221&222, siRNA scrambled, and siRNA PTEN. H460 transfected cells
showed a decrease of G1 and a corresponding increase of the S and G2-M phases, as a consequence of PTEN downregulation.
(B and C) MiR-221&222 regulate cell migration ability in H460 cells. Migration assay was performed as described in the Experimental Procedures.
(D) miR-221&222 influences H460 and Sk-Hep1 cell invasion ability. Histogram reports the percentage of cells that invaded through Matrigel-coated membrane
after transfection with negative control miRNA, miR-221, miR-222, siPTEN, and siTIMP3. One-way analysis of variance was performed to test the differences
among means of invasion values. The Scheffe multiple-comparison method was used to test the differences between each pair of means. Significant differences
were found between the scrambled versus miR-221&222, PTEN, and TIMP3 H460 transfected cells (p < 0.001). The same results were obtained using the
Bonferroni and Sidak methods. Error bars indicate ± SD. *p < 0.001 by Student’s t test. Scale bar indicates 25 mm. The magnification is the same for all panels.Huh7 cells, which show low levels of miR-221&222, with aniso-
mycin, an antibiotic able to activate JNK kinases and, thus,
AP-1, and we checked miR-221&222 and PTEN-TIMP3 expres-
sion levels. After c-Jun activation (Figure 7K) by anisomycin,
miR-221 and miR-222 expression increased (miR-221 = 80%
andmiR-222 = 40%) as confirmed by qRT-PCR (Figure 7J), while
PTEN and TIMP3 expression levels decreased drastically (Fig-
ure 7K). To further prove that JNK is the intermediate signaling
factor between c-Met and c-Jun and that c-Jun knockdown
leads to increased PTEN and TIMP3 expression, we silenced
c-Met and c-Jun in Calu-1 cells and analyzed the JNK1/2
phosphorylation and PTEN and TIMP3 expression, respectively.
As shown in Figure S7F, MET knockdown reduces JNK1/2
phosphorylation while c-Jun silencing increases PTEN/TIMP3
expression as a result of miR-221&222 downmodulation. To
corroborate the direct relation between MET and PTEN/TIMP3
also in vivo, immunohistochemistry analysis was performed on
lung and liver cancer and normal samples. The colabeling
MET/PTEN and MET/TIMP3 clearly shows that PTEN and
TIMP3 are abundantly expressed only in the normal cells, where
MET is not present, whereas c-Met is expressed exclusively in
the cancer cells (Figure S8). These data confirm that MET is
implicated in miR-221 and miR-222 regulation, at least in part
through JNK, AP-1, and in particular c-Jun transcription factor.CDISCUSSION
Lung cancer is the leading cause of cancer death in both men
and women worldwide. It is becoming apparent, through candi-
date gene and genome-wide approaches, that clinically evident
lung cancers accumulate numerous clonal genetic and epige-
netic alterations during a multistep process. These alterations
include tumor suppressor gene inactivation and activation of
growth or survival promoting oncogenes (Sekido et al., 2003).
HCC is one of the most common causes of cancer-related death
worldwide and the principal cause of death among cirrhotic
patients (Sangiovanni et al., 2004) with an annual occurrence
of one million cases. The prognosis of HCC is poor, due to
frequent intrahepatic metastasis and tumor recurrence. One of
the most important factors that affect survival rate is resistance
to therapeutic drugs. Thus development of effective therapeutic
approaches is necessary for the management of these common
cancers. Due to their specific toxicity for malignant cells, re-
combinant forms of TRAIL are among the most promising
apoptosis-based antitumor agents (Walczak et al., 1999).
However, many human cancer cells remain resistant to TRAIL-
induced apoptosis, but the mechanism of such resistance is
not clear. MiRNAs are attractive drug targets since they regulate
expression of many cellular proteins and are differentiallyancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc. 505
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focused on two highly related miRs, miR-221 and miR-222,
differentially expressed in TRAIL-resistant and in TRAIL-sensi-
tive NSCLCs. Our experiments indicated that miR-221&222
modulated TRAIL sensitivity in lung cancer cells mainly by inter-
fering with p27kip1 expression and TRAIL-induced caspase
machinery. However, it seemed plausible that silencing of addi-
tional targets of miR-221 and miR-222 contributed to TRAIL
resistance in NSCLC cells. In the present study, we attempted
to identify major mRNA targets and signaling pathways that
mediate miR-221&222 regulation in a wide panel of NSCLC
and HCC-derived cell lines. In vitro and in vivo experiments
revealed that elevated levels of miR-221&222 in NSCLCs and
HCCs correlate with PTEN and TIMP3 downregulation, indi-
cating that these two miRNAs could be a causal factor in the
downregulation of PTEN and TIMP3 in these types of cancers.
The tumor suppressor PTEN regulates the PI3K/AKT pathway,
Figure 7. MET Oncogene Regulates miR-
221&222 Activation
(A–C) Relative expression levels of miR-221&222
in Calu-1, Snu-387, and GTL16 after transfection
with miR control and siRNA MET. MiR-221&222
expression decreased after MET knockdown.
(D–F) Western blots after siRNA MET transfection
in Calu-1, Snu-387, and GTL16 cells. MET knock-
down decreased miR-221&222 expression levels,
giving rise to PTEN and TIMP3 upregulation in all
the different cell lines. Moreover, GTL16 cells
were treated for 24 hr with 4 mM of the MET inhib-
itor SU11274. MET inhibition increased miR-
221&222 target expression levels.
(G–I) Identification of c-Jun (AP-1) interacting
region using two different amplicons across the
miR-221&222 transcription start site. ChIP analysis
was performed with chromatin from H460 c-Jun-
negative cells and Calu-1 and Snu-387 c-Jun-
positive cells. BS, binding site.
(J) qRT-PCR of miR-221&222 in Huh7 cells after
treatment with anisomycin (10 mM) for 30 min. Ani-
somycin induced miR-221&222 upregulation.
(K) Anisomycin induced c-Jun activation and PTEN
and TIMP3 downregulation in Huh7 cells. Total
lysate was analyzed by western blot using
anti-PTEN and anti-TIMP3 antibody. Error bars
indicate ± SD.
a major cell survival pathway, playing
a key role in the development of multiple
drug resistance, including that to TRAIL
(Kandasamy and Srivastava, 2002).
TIMP3 has been reported to induce the
activation of both initiator caspases-8
and -9 (Lee et al., 2008a). Therefore, we
examined the effects of miR-221&222
and their targets on cell survival and
TRAIL resistance. Interestingly, we found
that after miR-221&222 enforced expres-
sion, or PTEN and TIMP3 downregula-
tion, TRAIL-sensitive NSCLC and HCC
cells became resistant to TRAIL-inducing
apoptosis, although PTEN downregulation was slightly more
effective than that of TIMP3. Our results clearly indicate that
miR-221&222 overexpression is a ‘‘prerequisite’’ of TRAIL-resis-
tant NSCLC and HCC cells, corroborating previous indications
that the expression levels of few miRNAs could sensitize cancer
cells to drug-inducing cell death. Importantly, tumor stratifica-
tion, on the basis of miR-221&222 expression levels, could be
used as prognostic tool to predict TRAIL sensitivity or resistance
in the treatment of NSCLCs and HCCs. Although many data
already exist, establishing an important role for miRNAs in the
pathogenesis of cancer, the molecular mechanisms by which
miRNAs can regulate tumor growth, invasion, or metastasis are
still in their infancy. It has been well documented that constitutive
activation of AKT contributes to cell migration and invasion in
different types of tumors, including lung (Fong et al., 2008) and
liver carcinoma. Our data indicate that miR-221&222 block
PTEN expression leading to activation of the AKT pathway,506 Cancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc.
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growth and invasiveness by targeting the PTEN/AKT pathway.
In this regard cell-cycle analysis showed an increase in cell
growth tightly linked to the G1 to S shift, which is in agreement
with modulation of PTEN and also of p27kip1, a known regulator
of the G1/S cell-cycle checkpoint and a downstream effector of
PTEN. We report here that NSCLC and HCC cells overexpress-
ingmiR-221&222 are not only TRAIL resistant but they also show
an increase in migration and invasion capabilities, compared to
cells expressing lower levels of miR-221&222 cells. Our experi-
ments demonstrate that miR-221&222 promote cell migration,
invasion, and growth via direct repression of PTEN and TIMP3
expression and of downstream pathways involving AKT and
ERKs phosphorylation, and the activation of MMP-3 and
MMP-9. Moreover, PTEN and TIMP3 loss in H460 tumor xeno-
graft conferred not only a significant tumor growth advantage
but also a resistance to TRAIL-inducing apoptosis over control
tumors also in vivo. Interestingly, the TIMP3 knockdown tumors
were more vascularized than the control tumors, highlighting its
role in angiogenesis and tumor formation (Janssen et al., 2008).
A recent study has shown that miR-21 regulates multiple genes
associated with glioma migration and invasiveness, including
TIMP3, although indirectly (Gabriely et al., 2008). In fact, the
TIMP3 30UTR construct did not consistently respond to changes
in miR-21 levels. The identification of miR-221&222 as important
regulators of tumor cell proliferation, migration, and invasion of
NSCLC and HCC, in vitro and in vivo, provides insights into the
role of these miRNAs in hepatic and lung oncogenesis and tumor
behavior. miR-221&222 are among the most deregulated
miRNAs implicated in cancer (Volinia et al., 2006). Their expres-
sion is highly upregulated in a variety of solid tumors, including
thyroid cancer (Pallante et al., 2006), hepatocarcinoma (Fornari
et al., 2008), and melanoma (Felicetti et al., 2008) cells. Elevated
miR-221&222 expression has been causally linked to proliferation
(le Sage et al., 2007), apoptosis, (Garofalo et al., 2008a), and
migration (Felicetti et al., 2008) of several cancer cell lines.
However, our knowledge of the molecular mechanisms mediating
miR-221&222 function in cancer generally, and in NSCLC and
HCC specifically, has been limited. Here, we provide evidence
that the activation of miR-221&222 is regulated, at least in part,
by the MET oncogene and the c-Jun transcription factor. Activa-
tion of MET signaling is a frequent genetic event observed in liver
and lung cancer development (Patil et al., 2009). AP-1 is a
complex of dimeric basic region leucine zipper proteins that
belong to the Jun (c-Jun, JunB, and JunD), Fos (c-Fos, FosB,
Fra-1, and Fra-2), Maf, and ATF subfamilies. c-Jun is the most
potent transcriptional activator in its group (Ryseck and Bravo,
1991) whose transcriptional activity is attenuated and sometimes
antagonized by JunB (Chiu et al., 1989). The Fos proteins, which
cannot homodimerize, formstable heterodimerswithJun proteins
and thereby enhance their DNA binding activity. We focused on
these two AP-1 subfamilies, and in particular on c-Jun and c-Fos,
although we found by bioinformatics search (TESS database)
that ATF-1 and JunD also could be potential transcription factors
involved inmiR-221&222activation. Ourexperimentsdemonstrate
that c-Jun and not c-Fos is involved inmiR-221&222activationand
that c-Jun has one binding site in the miR-221&222 promoter
region. The induction of AP-1 is mostly mediated by the JNK
cascades. By using anisomycin, an antibiotic that activates theCJNK cascade, we found an increase of miR-221&222 expression
in Huh7 hepatocarcinoma cells, as a consequence of c-Jun phos-
phorylation. Intriguingly, when we grew Huh7 cells in serum-free
medium, we did not observe any variation in the expression level
of miR-221&222 or PTEN and TIMP3 (data not shown), suggest-
ing that MET activation is important for miR-221&222 transcrip-
tion regulation and subsequent cellular migration. To address
this issue we investigated Calu-1 and Snu-387 cell migration
and invasion after MET silencing. As expected, migratory and
invasive capabilities of both cell lines were clearly reduced after
MET oncogene silencing (Figures S9A and S9B). Furthermore,
a xenograft model of Calu-1 cells in which c-Met was silenced
using an shMET plasmid (Figure S9C) clearly showed that mice
injected with Calu-1 shMET cells are more sensitive to TRAIL-
inducing apoptosis compared to the mice injected with the sh
control (Figures S9D and S9E). Thus, MET confers not only
a tumor growth advantage but also resistance to TRAIL-inducing
apoptosis over control tumors in vivo. Therefore, MET oncogene
regulates miR-221&222 levels and, accordingly, cellular invasion
and migration through c-Jun transcription factor and JNK activa-
tion (Figure 8). Taken together, these data highlight a mechanism,
involving MET, through which miR-221&222 could promote
tumorigenesis and metastasis. Thus, approaches targeting
MET receptor and/or miR-221&222 could be used not only to
sensitize NSCLC and HCC to TRAIL-inducing apoptosis but
also in the prevention and inhibition of lung cancer and HCC.
Figure 8. MET Induces miR-221&222 Activation through AP-1
(c-Jun) Transcription Factor
A model is reported in which growth factors determine c-Met activation, which,
in turn, through AP-1 and accordingly miR-221&222 upregulation, gives rise to
PTEN and TIMP3 downregulation and subsequent apoptosis resistance,
cellular migration, and invasion.ancer Cell 16, 498–509, December 8, 2009 ª2009 Elsevier Inc. 507
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Luciferase Assay
The 30UTR of the humanPTEN and TIMP3 genes were PCR amplified using the
following primers: PTEN forward (Fw), 50-TCTAGAGACTCTGATCCAGAGAAT
GAACC-30, and PTEN reverse (Rw), 50-TCTAGAGTTGCCACAAGTGCAAAG
GGGTAGGATGTG-30; TIMP3 Fw, 50-TCTAGACTGGGCAAAGAAGGGTCTTT
CGCAAAGC-30, and TIMP3 Rw, 50-TCTAGATTCCAATAGGGAGGAGGCTG
GAGGAGTCTC-30. They were then cloned downstream of the Renilla lucif-
erase stop codon in pGL3 control vector (Promega), giving rise to the
p30UTR-PTEN and p30UTR-TIMP3 plasmids. These constructs were used to
generate, by inverse PCR, the p30UTRmut-PTEN plasmid (primers: Fw, 50-GT
TGAAAAAAGGTTGGGGGCGGGTGTCATGTATATAC-3; Rw, 50-GTATATACA
TGACACCCGCCCCCAACCTTTTTTCAAC-30) and p30UTRmut-TIMP3 plas-
mid (primers: Fw, 50-GTATAATTTAAAATCATTGGGCGGCGGGAGACACTTC
TGTATTTC-30; Rw, 50-GAAATACAGAAGTGTCTCCCGCCGCCCAATGATTT
TAAATTATAC-30). MeG01 cells were cotransfected with 1 mg of p30UTR-
PTEN or p30UTR-TIMP3 and with p30UTRmut-PTEN or p30UTR-TIMP3 plas-
mids and 1 mg of a Renilla luciferase expression construct, pRL-TK (Promega),
using Lipofectamine 2000 (Invitrogen). Cells were harvested 24 hr posttrans-
fection and assayed with Dual Luciferase Assay (Promega) according to the
manufacturer’s instructions. Three independent experiments were performed
in triplicate.
Lung and Liver Cancer Samples and Cell Lines
A total of 32 snap-frozen normal and malignant lung tissues (19 men and
13 women, median age: 70.0, range: 55–82) and 60 snap-frozen normal and
60 malignant liver tissues were collected at the Ohio State University Medical
Center (Columbus, OH). Other 72 cancer and normal (24) lung tissues were
purchased from US Biomax, Inc. The human tissues were obtained and studied
in strict adherence to the Ohio State University Institutional Review Board-
approved protocol. This protocol, since biopsy material already obtained and
embedded in paraffin was used, was exempt from informed consent. As per
the policy of the associated HIPAA waiver, all patient health information was
kept strictly confidential. Finally, tissue microarrays from an outside source
were also used and, since these did not contain any patient health information,
Institutional Review Board protocols and informed consent were not applicable.
In Vivo Experiments
Animal studies were performed according to institutional guidelines. NCI-H460
cells were stable transfected using shPTEN and TIMP3 plasmids (Santa Cruz
Biotechnology, Inc.); Calu-1 cells were stable transfected with shMET. After
the selection in puromycin for 10 days, 53 106 (H460) or 73 106 (Calu-1) viable
cells were injected subcutaneously into the right flanks of 6-wk-old male nude
mice (Charles RiverBreeding Laboratories). Treatment started 5 days (H460
xenograft) or 10 days (Calu-1 xenograft) from tumor cell inoculation by daily
i.p. injections of TRAIL/Apo2 (10 mg/kg/day) or vehicle (PBS) for two cycles
of 5 days. Tumor size was assessed every 5 days by a digital caliper. The tumor
volumes were determined by measuring the length (l) and the width (w) and
calculating the volume (V = lw2/2). Thirty-five days after injection, mice were
sacrificed and tumor samples were analyzed by western blot for PTEN,
TIMP3, and MET expression. Statistical significance between control and
treated animals was evaluated using Student’s t test. Animal experiments
were conducted after approval of the Institutional animal care and use
committee, Ohio State University.
Statistical Analysis
Student’s t test and one-way analysis of variance was used to determine
significance. All error bars represent the standard error of the mean. Pearson
correlation coefficient was calculated to test the association between miR-
221&222 and PTEN in the classes normal versus tumor. Statistical significance
for all the tests, assessed by calculating p value, was <0.05.
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